Allergan (AGN) is shifting its M&A efforts toward smaller-sized deals as it works to boost its investment-grade rating after the $40.5 billion sale of its generics business to Teva Pharmaceutical (TEVA) is completed, the company's CEO told attendees at the UBS Global Healthcare Conference on Monday.
"We did purposely pivot a little on our thinking around capital deployment and M&A," CEO Brent Saunders said at the Grand Hyatt New York in a fireside chat with UBS analyst Marc Goodman.
"We did purposely pivot a little on our thinking around capital deployment and M&A," CEO Brent Saunders said at the Grand Hyatt New York in a fireside chat with UBS analyst Marc Goodman.
